A Multicenter, Open-Label, Non-Randomized Study to Assess the Pharmacokinetics, Tolerability, and Safety of a Single Subcutaneous Administration of Icatibant in Children and Adolescents With Hereditary Angioedema
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 09 Feb 2017
At a glance
- Drugs Icatibant (Primary)
- Indications Hereditary angioedema
- Focus Adverse reactions; Pharmacokinetics; Registrational
- Sponsors Shire
- 06 Feb 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2017.
- 04 Aug 2016 Planned End Date changed from 1 Mar 2017 to 1 Dec 2017.
- 04 Aug 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Sep 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History